UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (132) 132
life sciences & biomedicine (130) 130
oncology (96) 96
humans (90) 90
lung neoplasms - drug therapy (52) 52
male (49) 49
carcinoma, non-small-cell lung - drug therapy (48) 48
female (46) 46
middle aged (45) 45
lung cancer (44) 44
aged (38) 38
chemotherapy (35) 35
lung neoplasms - genetics (35) 35
carcinoma, non-small-cell lung - genetics (33) 33
adult (31) 31
lung neoplasms - pathology (31) 31
mutation (31) 31
carcinoma, non-small-cell lung - pathology (27) 27
respiratory system (27) 27
lung cancer, non-small cell (26) 26
nsclc (24) 24
lung neoplasms - mortality (23) 23
non-small cell lung carcinoma (23) 23
prognosis (23) 23
metastasis (22) 22
aged, 80 and over (20) 20
antineoplastic agents - therapeutic use (20) 20
cancer (20) 20
neoplasm staging (20) 20
patients (20) 20
carcinoma, non-small-cell lung - mortality (19) 19
care and treatment (19) 19
treatment outcome (19) 19
tumors (18) 18
cancer therapies (17) 17
protein kinase inhibitors - therapeutic use (17) 17
immunotherapy (16) 16
disease-free survival (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
erbb receptors - genetics (14) 14
blasting (13) 13
heating (13) 13
lighting (13) 13
mechanical engineering (13) 13
weapons (13) 13
life sciences (12) 12
non-small cell lung cancer (12) 12
protein kinase inhibitors - adverse effects (12) 12
clinical trials (11) 11
crizotinib (11) 11
general & internal medicine (11) 11
general tagging of cross-sectional technologies spanning over several sections of the ipc (11) 11
general tagging of new technological developments (11) 11
kaplan-meier estimate (11) 11
lung neoplasms - diagnosis (11) 11
receptor protein-tyrosine kinases - genetics (11) 11
survival (11) 11
technical subjects covered by former uspc (11) 11
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (11) 11
antineoplastic agents - adverse effects (10) 10
biomarkers (10) 10
biomarkers, tumor (10) 10
hematology, oncology and palliative medicine (10) 10
medical research (10) 10
medicine, general & internal (10) 10
research (10) 10
small cell lung carcinoma (10) 10
abridged index medicus (9) 9
antibodies, monoclonal - therapeutic use (9) 9
disease progression (9) 9
egfr (9) 9
medical prognosis (9) 9
neoplasm metastasis (9) 9
non-small-cell lung cancer (9) 9
retrospective studies (9) 9
studies (9) 9
analysis (8) 8
drug resistance, neoplasm - genetics (8) 8
drug therapy (8) 8
epidermal growth factor receptors (8) 8
lung neoplasms - therapy (8) 8
melanoma (8) 8
metastases (8) 8
survival analysis (8) 8
survival rate (8) 8
carcinoma, non-small-cell lung - diagnosis (7) 7
cell survival (7) 7
cisplatin (7) 7
epidermal growth factor (7) 7
follow-up studies (7) 7
genetic aspects (7) 7
measuring (7) 7
physics (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
protein-tyrosine kinase (7) 7
risk factors (7) 7
testing (7) 7
tyrosine (7) 7
[sdv.can]life sciences [q-bio]/cancer (6) 6
actuating-floats (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 12/2018, Volume 379, Issue 24, pp. 2342 - 2350
Journal Article
The lancet oncology, ISSN 1470-2045, 03/2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2017, Volume 377, Issue 20, pp. 1919 - 1929
Journal Article
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2020, Volume 383, Issue 18, pp. 1780 - 1782
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. 984 - 993
Summary Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).... 
Hematology, Oncology and Palliative Medicine
Journal Article
The European respiratory journal, ISSN 0903-1936, 08/2017, Volume 50, Issue 2, pp. 1700050 - 1700050
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung... 
Pneumonitis | Immune checkpoint | Cell death | Lung diseases | Immunotherapy | Hypersensitivity | Lung cancer | Melanoma | Alveolitis | Cancer | Apoptosis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article